Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Net Margin
Basilea Pharmaceutica AG

-0.4%
Current
0.4%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-0.4%
=
Net Income
-652k
/
Revenue
149m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CH
Basilea Pharmaceutica AG
SIX:BSLN
498.8m CHF
0%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
Country CH
Market Cap 498.8m CHF
Net Margin
0%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 318.1B USD
Net Margin
9%
Country US
Market Cap 142.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 105.2B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
No Stocks Found

Basilea Pharmaceutica AG
Glance View

Market Cap
498.8m CHF
Industry
Biotechnology

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

BSLN Intrinsic Value
75.14 CHF
Undervaluation 45%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-0.4%
=
Net Income
-652k
/
Revenue
149m
What is the Net Margin of Basilea Pharmaceutica AG?

Based on Basilea Pharmaceutica AG's most recent financial statements, the company has Net Margin of -0.4%.